Bestatin, a new immunomodulator, augments the release of mitogenic factors from PHA-stimulated human lymphocytes.
A new chemically well-defined immunomodulator termed Bestatin was examined for its capacity to interfere with the release of factors from PHA pulsed human peripheral lymphoid cells which are mitogenic for T-cells. The presence of Bestatin, at Concentrations of 0.01-100 microgram/ml, during PHA-pulsing significantly enhanced the subsequent release of mitogenic factors. The highest increase, fourfold, was observed using 10 microgram/ml of Bestatin, Treatment of lymphoid cells with Bestatin alone or pretreatment with this compound before PHA pulsing did not significantly change the subsequent release of these lymphokines.
D000328:Adult; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism*; D007700:Kinetics; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008222:Lymphokines / Q000378:metabolism*; D008297:Male; D010835:Phytohemagglutinins
D007376:Interleukin-2; D008222:Lymphokines; D010835:Phytohemagglutinins; D007930:Leucine; C012211:ubenimex